Stockscreener 앱 받기
54.46
0.61%
0.33
시간 외 거래:
54.46
Sanofi Adr 주식(SNY)의 최신 뉴스
Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease - GlobeNewswire Inc.
Validea Detailed Fundamental AnalysisSNY - Nasdaq
Harrow Earns Relative Strength Rating Upgrade - Inkl
Sanofi ADR Earns RS Rating Upgrade - Investor's Business Daily
Newmont Earns RS Rating Upgrade - Inkl
What was Skechers U S A, Inc (SKX)’s performance in the last session? - US Post News
Sanofi ADR (SNY) requires closer examination - US Post News
Sanofi ADR (SNY): A Technical Analysis - The News Heater
GNPX’s Market Whiplash: -38.94% YTD Decline, -42.28% Plunge in 30 Days - The InvestChronicle
Applied Materials Inc’s Banking’s 100-Day Moving Average at 182.60: Will the Stock Break Through? - The InvestChronicle
ESPR’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Regeneron Pharmaceuticals Beats On Libtayo's Back, Unveils Dividend - Investor's Business Daily
Waltham biotech plans to raise $150M in IPO this week - The Business Journals
Sanofi Reports Strong Q4 Sales Growth, Plans €5 Billion Buyback in 2025 - GuruFocus.com
Sanofi ADR earnings beat by $0.53, revenue fell short of estimates - Investing.com South Africa
Sanofi ADR (SNY) Recovers 15.33% From Low: Are We There Yet? - Stocks Register
Sanofi: Informations relatives au nombre de droits de vote et d'actions - GlobeNewswire Inc.
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
AECOM (NYSE: ACM) Is A Blank Check For Growth - Stocks Register
Shares Of Pennymac Mortgage Investment Trust (NYSE: PMT): Are They Overvalued Compared To Others? - Stocks Register
7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.
Gsk Plc ADR (GSK-N) QuotePress Release - The Globe and Mail
3 Pharma Stocks To Buy As California Sounds The Alarm On Bird Flu Cases - Barchart
Communiqué de presse - GlobeNewswire Inc.
Teva Pharmaceutical ADR Clears Technical Benchmark, Hitting 90-Plus RS Rating - Investor's Business Daily
10 Best Blue-Chip Stocks to Buy for the Long Term - Morningstar
Teva Catapults 26%, Hitting A Six-Year High, After Scoring A Win With Sanofi-Tied Drug - Investor's Business Daily
What Did We Find About Insider Trading At Sanofi ADR (NASDAQ: SNY)? - Stocks Register
0.07%
1.54%
자본화:
|
볼륨(24시간):